NEW YORK (GenomeWeb) – Waters today announced that it will establish a joint open laboratory with the Chinese Pharmacopoeia Commission.

The lab, which will be located in the Beijing Zhendong Guangming Drug Research Institute, is slated to open by the end of the year. Activities there will be directed at research into pharmacopoeia standards, developing testing methods, validating the methods, and providing training in pharmacopoeia detection methods. The lab, the partners said, is anticipated to become a national technical support center in Chinese pharmaceutical standards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.